Early Cancer Institute Seminar: Dr Michael Cook, Our Future Health

Early Cancer Institute Seminar: Dr Michael Cook, Our Future Health

Dr Michael Cook from Our Future Health will talk about a new 5-million-person prospective cohort study.

By Cancer Research UK Cambridge Centre

Date and time

Tue, 6 Feb 2024 12:30 - 14:00 GMT

Location

Early Cancer Institute, University of Cambridge

Adrian Way Cambridge CB2 0XZ United Kingdom

About this event

The seminar series from the Early Cancer Institute aims to connect researchers in the early cancer detection and diagnosis space to share knowledge and spark collaboration. Join fellow researchers for lunch and an opportunity to network.

On Tuesday 6th February we welcome Dr Michael Cook, Executive Director of Science at Our Future Health, to give a talk: 'Our Future Health – a new translational prospective cohort study.'

This event will take place in the Early Cancer Institute, Adrian Way, Cambridge Biomedical Campus, Cambridge, CB2 0XZ

Lunch is provided from 12:30pm, the talk will begin at 1.00pm followed by a Q&A. Please ensure you arrive promptly.


Speaker Biography:

Michael is the Executive Director of Science at Our Future Health, a UK-based charity that is developing a new 5-million-person prospective cohort study. He leads and oversees all scientific aspects of the study, which has led to our current state of having recruited one million participants. Michael was previously a tenured, Senior Investigator at the US National Institutes of Health. He has extensive experience in molecular epidemiology with broad and contemporary expertise in research (biomarkers, statistics, epidemiology), program management, and scientific leadership.

Organised by

Cancer Research UK Cambridge Centre

The Cancer Research UK Cambridge Centre unites over 1,000 world-leading biologists, chemists, physicists, engineers, mathematicians, computer scientists, clinicians, nurses and allied healthcare professionals from across Cambridge, UK to tackle cancer from every angle.

Our mission is to end death and disease caused by cancer through research, treatment and education. We are detecting cancer at its earliest stage and are developing personalised treatments for every patient through facilitating new collaborations and driving the translation of new scientific discoveries into clinical applications to improve patient care. By working together across a range of different disciplines, our members are breaking down the barriers between the laboratory and the clinic, enabling patients to benefit from the latest innovations in cancer science.

Sales Ended